What is The Story on Synta

Synta Pharmaceuticals Corp (NASDAQ: SNTA) is a biotechnology firm focused on the discovery, development and commercialization of small molecule drugs indicated for the treatment of cancer and inflammatory diseases. The stock has been picking up momentum since Wednesday June 2, 2014 due to the positive overall trend in insiders accumulations, as well as, buy out speculations.

 
Source: OpenInsider

How is The Stock Trading Recently

Synta traded in the range of $3.70 PS to $7.85 PS for the past 52-weeks. The company has a market capitalization of $406.72 million. During the Thursday's trading session, shares exchanged hands from $4.18 to $4.54, and the stock closed at $7.85 or 7.9 percent higher than the prior session.

Source: Finviz

Tell Me More About The Company 

Synta has a unique chemical compound library, an integrated pharmacotherapy discovery platform, and notably an interesting pipeline of clinical- and preclinical-stage drugs different types of cancers. As of the end of 2011, the company has two drug candidates in clinical trials including Ganetespib and Hsp90 inhibitor drug conjugates (HDC).

Source: Synta Pharmaceuticals

Keep reading >